Core Viewpoint - Tianmu Pharmaceutical has experienced a significant turnaround in its financial performance in 2024, primarily due to increased revenue from health products and medical training services, largely supported by local enterprises in Qingdao [2][3][4]. Financial Performance - Tianmu Pharmaceutical's revenue for the first half of 2024 was 0.6 billion, with a net profit of -0.19 billion [3]. - In the second half of 2024, the company's revenue surged to 1.58 billion, accounting for 72.59% of the total annual revenue, with a net profit of 0.34 billion [4]. - The fourth quarter alone contributed 0.93 billion in revenue, representing 42.62% of the annual total [4]. Business Segments - Health products became the largest business segment for Tianmu Pharmaceutical in 2024, generating 0.68 billion in revenue, a 322% increase year-on-year [5]. - Medical training services followed, with revenue of 0.43 billion, marking a 286% increase [5]. Customer Base and Relationships - Eight out of the top ten customers for Tianmu Pharmaceutical's health products in 2024 were Qingdao-based companies, with six being construction-related firms [5]. - The company has been questioned regarding the sustainability of its new customer relationships, particularly with local construction firms linked to its controlling shareholder [5][6]. Acquisitions and Projects - In 2024, Tianmu Pharmaceutical acquired a 51% stake in Qingdao Simulation Medicine, which significantly contributed to its revenue growth [6]. - Qingdao Simulation Medicine won a project from the Qingdao Health Commission worth 39.55 million, enhancing Tianmu's financial performance [6][9]. Future Outlook - The sustainability of the revenue growth from Qingdao Simulation Medicine is under scrutiny, with the company planning to enhance its capabilities and pursue additional contracts for 2025 [10].

Core Viewpoint - The company Kyowa Kirin announced a voluntary early retirement plan for employees aged 40 and above with at least three years of service, recognizing the increasing challenges faced by global pharmaceutical companies [1] Group 1: Company Actions - The application period for the early retirement plan is set from May 22 to June 24 [1] - The company aims to transform its long-established business foundation in Japan to enhance sustainability and strengthen organizational capabilities [1] Group 2: Industry Context - The pharmaceutical industry is facing significant challenges globally, exacerbated by Japan's declining population and rapid aging society, which highlight major issues related to healthcare sustainability [1]